Victoria K. Hicks

Victoria K. Hicks

Auto-generated profile, based on publicly available information

Victoria K. Hicks

Wye Valley NHS Trust, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2017 in Science Advances
Verified
Journal Article
Open access
PDF file
CSCharles B. Sweeney
Charles B. Sweeney
BLBlake A. Lackey
Blake A. Lackey
MPMartin J. Pospisil
Martin J. Pospisil
TAThomas C. Achee
Thomas C. Achee
VHVictoria K. Hicks
Victoria K. Hicks
MGMicah J. Green
Micah J. Green
RF heating of carbon nanotubes enables local welding and increased strength between 3D-printed thermoplastic layers.

6 April 2021 in Journal of Clinical Urology
Verified
Journal Article
Open access
PDF file
JOJonathan J Ord
Jonathan J Ord
MCMatthew Crockett
Matthew Crockett
JGJes Green
Jes Green
LBLawrence To Bell
Lawrence To Bell
VHVictoria Hicks
Victoria Hicks
JEJonathan Eaton
Jonathan Eaton
This study aimed to compare Likert scores with radical prostatectomy specimens. This study examined 443 men with validated pre-biopsy magnetic resonance imaging results and used cross-tabulation and chi-square significance testing with National Comprehensive Cancer Network risk categories. The mean prostate-specific antigen (PSA) was 10, and the mean age was 64 years. Comparing Likert III to Likert V and Likert IV to Likert V, both (each p=0.02) were significantly associated with higher prostate cancer risk groups, but Likert III versus Likert IV was not (p=0.1). Within the subgroup PSA density (PSAD) 0.15 (n=281; p=0.045 III vs. IV only and p=0.055 overall). Within the subgroup age 60 (n=339) this significant difference was lost (p=0.34). Further subgroup analysis within Likert III (n=86) found that men <60 (n=22) had neither high-grade (G3 or G4 or G5) nor very high-risk disease. There were only two high-risk cases, both of which were G2T3a (2/22; 10%). In men with Likert III and PSAD <0.15 (n=31), there were seven high-risk and two very high-risk cases (9/31; 25%). This difference was not significant (p=0.31) With these two findings, we recommend that men <60 with Likert III can be counselled like men with Likert III and PSAD <0.15, that they are unlikely to have unfavourable or high-risk disease and that they may wish to avoid biopsy or treatment. Level 1b.